Buprenorphine–naloxone “microdosing”: an alternative induction approach for the treatment of opioid use disorder in the wake of North America’s increasingly potent illicit drug market
Privia A. Randhawa, Rupinder Brar, Seonaid Nolan
Abstract
After reviewing the guideline by Bruneau and colleagues,[1][1] we agree that appropriate therapy should be used to manage opioid use disorders, with buprenorphine–naloxone being a first-line option. A substantial limitation of this medication, however, is the need for patients to abstain from
Topics & Concepts
Buprenorphine(+)-NaloxoneOpioid use disorderGuidelineMedicineOpioidNarcotic antagonistsDrugAnesthesiaPsychiatryPharmacologyInternal medicineReceptorPathologyOpioid Use Disorder TreatmentPain Management and Opioid UseTreatment of Major Depression